gavel-istock-174197278
Mari / iStockphoto.com
10 February 2017Americas

Sanofi and Regeneron secure stay of Praluent injunction

Sanofi and Regeneron have secured a stay of an injunction that would have blocked the companies from selling their cholesterol-lowering drug Praluent (alirocumab) injection.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
6 October 2017   The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.
Generics
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
30 October 2020   French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.

More on this story

Americas
6 October 2017   The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.
Generics
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
30 October 2020   French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.

More on this story

Americas
6 October 2017   The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.
Generics
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
30 October 2020   French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.